# What separate Alzheimer’s studies measured for these two molecules

- Article ID: research-330
- Product: SEMA / IGF-1 LR3 (sema-igf-1-lr3-708, sema-igf-1-lr3-709)
- Canonical page: https://heritagebiolabs.com/research-library/articles/330-what-separate-alzheimers-studies-measured-for-these-two-molecules
- Product collection: https://heritagebiolabs.com/research-library/products/sema-igf-1-lr3
- Product page: https://heritagebiolabs.com/product/sema-igf-1-lr3-708
- Product page: https://heritagebiolabs.com/product/sema-igf-1-lr3-709
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2024, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains connected by peptide bonds. Some activate receptors and change how cells handle signals. Semaglutide is a modified GLP-1 receptor agonist peptide. IGF-1 LR3 is an engineered growth-factor protein. Researchers have studied each in connection with Alzheimer’s disease in very different settings. The human semaglutide trials and an older IGF-1 LR3 mouse experiment show how the choice of outcome shapes the conclusion. [1, 2]

The evoke and evoke+ trials randomly assigned people with early symptomatic Alzheimer’s disease to oral semaglutide or placebo. The main comparison assessed change in a clinical scale that combines observations about cognition and daily function. At 104 weeks, neither trial found a significant difference in progression on that measure. These trials were designed to test the clinical outcome in people who already had early symptoms. [1]

In a separate study, investigators tested IGF-1 LR3 in male mice engineered to develop some features of Alzheimer’s disease. The researchers examined the animals’ behavior and brain tissue. They reported changes in certain amyloid plaque measurements, but they did not observe a significant preservation of cognitive function in their tests. Changes in tissue pathology and changes in performance were separate outcomes, even within this one experiment. [2]

Reading these findings together can help identify what was measured at each level. The mouse tissue findings concern a growth-factor analog in a particular model. The clinical scale findings concern a particular semaglutide formulation and population. Neither study included both molecules. There is no comparative clinical result for the catalog pair in these sources, and the investigated uses do not establish an Alzheimer’s indication. [1, 2, 3]

## Sources

1. Jeffrey L. Cummings et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet (publication 2026-03-19). <https://pubmed.ncbi.nlm.nih.gov/41865758/>
2. M. G. Engel et al. Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. Journal of Alzheimer’s Disease (publication 2024-11-29). <https://pubmed.ncbi.nlm.nih.gov/39610283/>
3. U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Drugs@FDA (publication 2026-06). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 066 - Selank and SEMA IGF-1 LR3.docx; article 330; content SHA-256 c92ae56917261ad1d2318036b2447ddd56636fc99dd3b7d484814c2a31e4bd60.
